Treatment on the Spleen Prevents the Progression of Secondary Sarcopenia in Patients With Liver Cirrhosis

Masashi Hirooka, Yohei Koizumi, Takaaki Tanaka, Yoshiko Nakamura, Koutarou Sunago, Atsushi Yukimoto, Takao Watanabe, Osamu Yoshida, Teruki Miyake, Yoshio Tokumoto, Bunzo Matsuura, Masanori Abe, Yoichi Hiasa – 31 October 2020 – Hyperammonemia is an important stimulator of myostatin expression, a negative regulator of muscle growth. After splenectomy or partial splenic artery embolization (PSE), hyperammonemia often improves.

Nonalcoholic Fatty Liver Disease Screening in Type 2 Diabetes Mellitus Patients in the Primary Care Setting

Joana Vieira Barbosa, Michelle Lai – 31 October 2020 – Nonalcoholic fatty liver disease (NAFLD) is a major public health problem worldwide and the most common chronic liver disease. NAFLD currently affects approximately one in every four people in the United States, and its global burden is expected to rise in the next decades. Despite being a prevalent disease in the general population, only a minority of patients with NAFLD will develop nonalcoholic steatohepatitis (NASH) with advanced liver fibrosis (stage 3‐4 fibrosis) and liver‐related complications.

Identifying Modifiable Predictors of Long‐Term Survival in Liver Transplant Recipients With Diabetes Mellitus Using Machine Learning

Angeline Yasodhara, Victor Dong, Amirhossein Azhie, Anna Goldenberg, Mamatha Bhat – 28 October 2020 – Diabetes mellitus (DM) significantly impacts long‐term survival after liver transplantation (LT). We identified survival factors for LT recipients who had DM to inform preventive care using machine‐learning analysis. We analyzed risk factors for mortality in patients from across the United States using the Scientific Registry of Transplant Recipients (SRTR). Patients had undergone LT from 1987 to 2019, with a follow‐up of 6.47 years (standard deviation [SD] 5.95).

Subscribe to